Drug Trial Radar · NCT07622121
Treatment of Chronic Thyroid Eye Disease With MHB018A
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
135
Planned (sponsor's estimate)
Start
Sep 24, 2026
Primary completion
Jul 2028
Study completion Jul 2029
Sponsor
- Lead sponsor
- Minghui Pharmaceutical (Hangzhou) LtdIndustry
- Sponsor type
- Industry
- First posted
- Jun 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with chronic moderate-to-severe TED.
Conditions
- Thyroid Eye Disease, TED
Interventions
MHB018A injectionDrug
MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)
MHB018A injection PlaceboDrug
6 subcutaneous injections of MHB018A placebo once every 4 weeks (q4w)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proptosis response rate at Week 24Time frame: Week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hype Clinical Research
Coral Gables, Florida · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.